In human retinoblastoma Y79 cells okadaic acid-parthenolide co-treatment induces synergistic apoptotic effects, with PTEN as a key player

Cancer Biology and Therapy

Volumn 14, Issue 10, 2013, Pages 922-931

  Di Fiore, Riccardo ^a   Drago Ferrante, Rosa ^a   D'Anneo, Antonella ^a   Augello, Giuseppa ^b   Carlisi, Daniela ^a   De Blasio, Anna ^a   Giuliano, Michela ^a   Tesoriere, Giovanni ^c   Vento, Renza ^a,c  

^a UNIVERSITY OF PALERMO   (Italy)

^b CNR   (Italy)

^c TEMPLE UNIVERSITY   (United States)

Author keywords

Natural drugs; Okadaic acid; Oxidative stress; Parthenolide; PTEN Akt Mdm2 p53 pathway; Retinoblastoma; Synergistic apoptotic effects; Y79 cells

Indexed keywords

BUTHIONINE SULFOXIMINE; GLUTATHIONE; OKADAIC ACID; PARTHENOLIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CELL STRAIN Y79; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; HUMAN; HUMAN CELL; OXIDATIVE STRESS; RETINOBLASTOMA; TUMOR CELL LINE;

NATURAL DRUGS; OKADAIC ACID; OXIDATIVE STRESS; PARTHENOLIDE; PTEN/AKT/MDM2/P53 PATHWAY; RETINOBLASTOMA; SYNERGISTIC APOPTOTIC EFFECTS; Y79 CELLS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SHAPE; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; GENE EXPRESSION; GLUTATHIONE; HUMANS; OKADAIC ACID; OXIDATIVE STRESS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MDM2; PTEN PHOSPHOHYDROLASE; REACTIVE OXYGEN SPECIES; RETINOBLASTOMA; SESQUITERPENES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84885237554     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.25944     Document Type: Article

References (47)

1. Aerts I, Lumbroso-Le Rouic L, Gauthier-Villars M, Brisse H, Doz F, Desjardins L. Retinoblastoma. Orphanet J Rare Dis 2006; 1:31; PMID:16934146; http://dx.doi.org/10.1186/1750-1172-1-31
2. Goodrich D W. The retinoblastoma tumor-suppressor gene, the exception that proves the rule. Oncogene 2006; 25:5233-43; PMID:16936742; http://dx.doi. org/10.1038/sj.onc.1209616 (Pubitemid 44299082)
3. Giacinti C, Giordano A. RB and cell cycle progression. Oncogene 2006; 25:5220-7; PMID:16936740; http://dx.doi.org/10.1038/sj.onc.1209615 (Pubitemid 44299080)
4. Melamud A, Palekar R, Singh A. Retinoblastoma. Am Fam Physician 2006; 73:1039-44; PMID:16570739
5. Zhong X, Li Y, Peng F, Huang B, Lin J, Zhang W, Zheng J, Jiang R, Song G, Ge J. Identification of tumorigenic retinal stem-like cells in human solid retinoblastomas. Int J Cancer 2007; 121:2125-31; PMID:17565741; http://dx.doi.org/10.1002/ijc.22880 (Pubitemid 47585590)
6. Antoneli CB, Ribeiro KC, Steinhorst F, Novaes PE, Chojniak MM, Malogolowkin M. Treatment of retinoblastoma patients with chemoreduction plus local therapy: experience of the AC Camargo Hospital, Brazil. J Pediatr Hematol Oncol 2006; 28:342-5; PMID:16794500; http://dx.doi. org/10.1097/00043426- 200606000-00004 (Pubitemid 43970388)
7. Jehanne M, Mercier G, Doz F. Monitoring of oto-toxicity in young children receiving carboplatin for retinoblastoma. Pediatr Blood Cancer 2009; 53:1162; PMID:19479791; http://dx.doi.org/10.1002/pbc.22124
8. Marees T, van Leeuwen FE, de Boer MR, Imhof SM, Ringens PJ, Moll AC. Cancer mortality in long-term survivors of retinoblastoma. Eur J Cancer 2009; 45:3245-53; PMID:19493675; http://dx.doi. org/10.1016/j.ejca.2009.05.011
9. Giuliano M, Lauricella M, Vassallo E, Carabillò M, Vento R, Tesoriere G. Induction of apoptosis in human retinoblastoma cells by topoisomerase inhibitors. Invest Ophthalmol Vis Sci 1998; 39:1300-11; PMID:9660477 (Pubitemid 28307354)
10. Vento R, Giuliano M, Lauricella M, Carabillò M, Di Liberto D, Tesoriere G. Induction of programmed cell death in human retinoblastoma Y79 cells by C2-ceramide. Mol Cell Biochem 1998; 185:7-15; PMID:9746206; http://dx.doi. org/10.1023/A:1006836428202
11. Vento R, D'Alessandro N, Giuliano M, Lauricella M, Carabillò M, Tesoriere G. Induction of apoptosis by arachidonic acid in human retinoblastoma Y79 cells: involvement of oxidative stress. Exp Eye Res 2000; 70:503-17; PMID:10865999; http://dx.doi. org/10.1006/exer.1998.0810 (Pubitemid 30658892)
12. Giuliano M, Lauricella M, Calvaruso G, Carabillò M, Emanuele S, Vento R, Tesoriere G. The apoptotic effects and synergistic interaction of sodium butyr-ate and MG132 in human retinoblastoma Y79 cells. Cancer Res 1999; 59:5586-95; PMID:10554039 (Pubitemid 29526478)
13. Drago-Ferrante R, Santulli A, Di Fiore R, Giuliano M, Calvaruso G, Tesoriere G, Vento R. Low doses of paclitaxel potently induce apoptosis in human retino-blastoma Y79 cells by up-regulating E2F1. Int J Oncol 2008; 33:677-87; PMID:18813780
14. D'Anneo A, Augello G, Santulli A, Giuliano M, di Fiore R, Messina C, Tesoriere G, Vento R. Paclitaxel and beta-lapachone synergistically induce apoptosis in human retinoblastoma Y79 cells by downregulating the levels of phospho-Akt. J Cell Physiol 2010; 222:433-43; PMID:19918798; http://dx.doi.org/10.1002/jcp.21983
15. Pajak B, Gajkowska B, Orzechowski A. Molecular basis of parthenolide-dependent proapoptotic activity in cancer cells. Folia Histochem Cytobiol 2008; 46:129-35; PMID:18519227; http://dx.doi.org/10.2478/v10042-008- 0019-2
16. Kawasaki BT, Hurt EM, Kalathur M, Duhagon MA, Milner JA, Kim YS, Farrar WL. Effects of the sesquiter-pene lactone parthenolide on prostate tumor-initiating cells: An integrated molecular profiling approach. Prostate 2009; 69:827-37; PMID:19204913; http://dx.doi.org/10.1002/pros.20931
17. Guzman ML, Rossi RM, Karnischky L, Li X, Peterson DR, Howard DS, Jordan C T. The sesquiterpene lac-tone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 2005; 105:4163-9; PMID:15687234; http://dx.doi.org/10.1182/blood-2004-10-4135 (Pubitemid 40720758)
18. Carlisi D, D'Anneo A, Angileri L, Lauricella M, Emanuele S, Santulli A, Vento R, Tesoriere G. Parthenolide sensitizes hepatocellular carcinoma cells to TRAIL by inducing the expression of death receptors through inhibition of STAT3 activation. J Cell Physiol 2011; 226:1632-41; PMID:21413021; http://dx.doi. org/10.1002/jcp.22494
19. Koprowska K, Czyz M. Molecular mechanisms of parthenolide's action: Old drug with a new face. Postepy Hig Med Dosw (Online) 2010; 64:100-14; PMID:20354259
20. Bialojan C, Takai A. Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases. Specificity and kinetics. Biochem J 1988; 256:283-90; PMID:2851982
21. Rossini G P, Sgarbi N, Malaguti C. The toxic responses induced by okadaic acid involve processing of multiple caspase isoforms. Toxicon 2001; 39:763-70; PMID:11137534; http://dx.doi.org/10.1016/S0041-0101(00)00202-6 (Pubitemid 32012941)
22. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55; PMID:6382953; http://dx.doi.org/10.1016/0065-2571(84)90007-4
23. Kim YR, Eom JI, Kim SJ, Jeung HK, Cheong JW, Kim JS, Min YH. Myeloperoxidase expression as a potential determinant of parthenolide-induced apoptosis in leukemia bulk and leukemia stem cells. J Pharmacol Exp Ther 2010; 335:389-400; PMID:20699435; http://dx.doi.org/10.1124/jpet.110.169367
24. Kitagishi Y, Matsuda S. Redox regulation of tumor suppressor PTEN in cancer and aging (Review). [Review]. Int J Mol Med 2013; 31:511-5; PMID:23313933
25. Chang CJ, Freeman DJ, Wu H. PTEN regulates Mdm2 expression through the P1 promoter. J Biol Chem 2004; 279:29841-8; PMID:15090541; http://dx.doi.org/10. 1074/jbc.M401488200 (Pubitemid 38915868)
26. Boubacar T, Fatou S, Fousseyni T, Mariam S, Fatoumata DT, Toumani S, Abdoul-Aziz D, Marouf KM. A 30-month prospective study on the treatment of retinoblastoma in the Gabriel Toure Teaching Hospital, Bamako, Mali. Br J Ophthalmol 2010; 94:467-9; PMID:19822911; http://dx.doi.org/10.1136/bjo.2009. 159699
27. Laurie NA, Shih CS, Dyer MA. Targeting MDM2 and MDMX in retinoblastoma. Curr Cancer Drug Targets 2007; 7:689-95; PMID:18045074; http://dx.doi.org/10. 2174/156800907782418266 (Pubitemid 350074972)
28. Boutrid H, Jockovich ME, Murray TG, Piña Y, Feuer WJ, Lampidis TJ, Cebulla CM. Targeting hypoxia, a novel treatment for advanced retinoblas-toma. Invest Ophthalmol Vis Sci 2008; 49:2799-805; PMID:18326690; http://dx.doi.org/ 10.1167/iovs.08-1751
29. Rizzuti AE, Dunkel IJ, Abramson DH. The adverse events of chemotherapy for retinoblastoma: what are they? Do we know? Arch Ophthalmol 2008; 126:862-5; PMID:18541855; http://dx.doi.org/10.1001/archopht.126.6.862 (Pubitemid 351831340)
30. Bhanot A, Sharma R, Noolvi MN. Natural sources as potential anti-cancer agents: A review. Intl J Phytomed 2011; 3:9-26
31. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002; 14:381-95; PMID:11882383; http://dx.doi.org/10.1016/S0898-6568(01)00271-6 (Pubitemid 34214843)
32. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296:1655-7; PMID:12040186; http://dx.doi.org/10.1126/science.296.5573.1655 (Pubitemid 34579158)
33. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008; 27:5497-510; PMID:18794884; http://dx.doi.org/10.1038/onc. 2008.245
34. Valentinis B, Baserga R. IGF-I receptor signalling in transformation and differentiation. Mol Pathol 2001; 54:133-7; PMID:11376123; http://dx.doi. org/10.1136/mp.54.3.133 (Pubitemid 32539602)
35. Metz HE, Houghton AM. Insulin receptor substrate regulation of phosphoinositide 3-kinase. Clin Cancer Res 2011; 17:206-11; PMID:20966354; http://dx.doi. org/10.1158/1078-0432.CCR-10-0434
36. Giuliano M, Vento R, Lauricella M, Calvaruso G, Carabillo M, Tesoriere G. Role of insulin-like growth factors in autocrine growth of human retinoblas-toma Y79 cells. Eur J Biochem 1996; 236:523-32; PMID:8612625; http://dx.doi.org/10.1111/j.1432-1033.1996.00523.x (Pubitemid 26098836)
37. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3, 4, 5-trisphosphate. J Biol Chem 1998; 273:13375-8; PMID:9593664; http://dx.doi.org/10.1074/jbc.273.22.13375 (Pubitemid 28268370)
38. Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol 2009; 4:127-50; PMID:18767981; http://dx.doi.org/10.1146/annurev. pathol.4.110807.092311
39. Yin Y, Shen WH. PTEN: a new guardian of the genome. Oncogene 2008; 27:5443-53; PMID:18794879; http://dx.doi.org/10.1038/onc.2008.241
40. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275:1943-7; PMID:9072974; http://dx.doi.org/10.1126/science.275.5308.1943 (Pubitemid 27148818)
41. Li L, Ross AH. Why is PTEN an important tumor suppressor? J Cell Biochem 2007; 102:1368-74; PMID:17972252; http://dx.doi.org/10.1002/jcb.21593 (Pubitemid 350223940)
42. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007; 129:1261-74; PMID:17604717; http://dx.doi.org/10.1016/j. cell.2007.06.009 (Pubitemid 46962095)
43. Wu B, Wang X, Chi ZF, Hu R, Zhang R, Yang W, Liu ZG. Ursolic acid-induced apoptosis in K562 cells involving upregulation of PTEN gene expression and inactivation of the PI3K/Akt pathway. Arch Pharm Res 2012; 35:543-8; PMID:22477202; http://dx.doi. org/10.1007/s12272-012-0318-1
44. Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ther 2005; 4:139-63; PMID:15725726; http://dx.doi.org/10.4161/cbt.4.2.1508 (Pubitemid 41351311)
45. Skulachev V P. Why are mitochondria involved in apoptosis? Permeability transition pores and apoptosis as selective mechanisms to eliminate superoxide-pro-ducing mitochondria and cell. FEBS Lett 1996; 397:7-10; PMID:8941703; http://dx.doi.org/10.1016/0014-5793(96)00989-1 (Pubitemid 26380163)
46. Valdiglesias V, Laffon B, Pásaro E, Cemeli E, Anderson D, Méndez J. Induction of oxidative DNA damage by the marine toxin okadaic acid depends on human cell type. Toxicon 2011; 57:882-8; PMID:21396392; http://dx.doi.org/10.1016/j.toxicon.2011.03.005
47. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol 1983; 32:671-6